
CAS 1610882-30-8
:TCS-OX2-29 HCl
- TCS-OX2-29 HCl
- TCSOX229 HCl,TCS-OX-2-29 HCl,TCS OX2 29 HCl
- (2S)-1-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-3,3-dimethyl-2-(pyridin-4-ylmethylamino)butan-1-one:hydrochloride
TCS OX2 29
CAS:TCS OX2 29 is a vasoactive intestinal peptide (VIP) receptor agonist that has been shown to have analgesic effects in rats. TCS OX2 29 is an excitatory neurotransmitter, which may be due to its ability to stimulate the release of glutamate and increase the activity of postsynaptic receptors. TCS OX2 29 also has a significant interaction with antinociceptive drugs such as morphine, which may be due to its ability to activate opioid receptors. Patch-clamp experiments on tegmental neurons have shown that TCS OX2 29 increases the frequency of spontaneous action potentials in these cells. It also induces locomotor activity in mice and pain hypersensitivity in rats. TCS OX2 29 has been used as an experimental model for symptoms associated with Parkinson’s disease, such as akinesia and muscle rigidity.
Formel:C23H31N3O3·HClReinheit:Min. 95%Molekulargewicht:433.97 g/molTCS-OX2-29 HCl
CAS:TCS-OX2-29 is a selective orexin-2 receptor antagonist (IC50 = 40 nM), which plays an important role in pain modulation.Formel:C23H32ClN3O3Reinheit:98%Farbe und Form:SolidMolekulargewicht:433.97


